Evidence map›Paper›PMID 41298726›Full record

Trial reportScientific reports2025

Grey matter volume reduction and its association with brain-enriched blood biomarkers in out-of-hospital cardiac arrest survivors.

Carita C Hollmén, Victor Vorobyev, Riitta Parkkola, Jussi P Posti, Jani Saunavaara, Ruut Laitio, Olli Arola, Marja Hynninen, Minna Bäcklund, Kaj Blennow and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00879892 (Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00879892 phase2completednot on this map

Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients

TypeinterventionalSponsorTurku University HospitalRan2009 to 2014Enrolled110ConditionsIschemic Brain InjuryArmsxenon, Hypothermia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Carita C HollménDepartment of Radiology, Turku University Hospital, University of Turku, Turku, Finland.
Victor VorobyevDepartment of Radiology, Turku University Hospital, University of Turku, Turku, Finland.
Riitta ParkkolaDepartment of Radiology, Turku University Hospital, University of Turku, Turku, Finland.
Jussi P PostiDepartment of Neurosurgery and Turku Brain Injury Center, Neurocenter, Turku University Hospital, Turku, Finland.
Jani SaunavaaraDepartment of Medical Physics, Turku University Hospital and University of Turku, Turku, Finland.
Ruut LaitioDepartment of Perioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital and University of Turku, Turku, Finland.
Olli ArolaDepartment of Perioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital and University of Turku, Turku, Finland.
Marja HynninenDivision of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Minna BäcklundDivision of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kaj Blennow⁷Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, S-431 80, Mölndal, Sweden.
Henrik Zetterberg⁷Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, S-431 80, Mölndal, Sweden.
Juha MartolaDepartment of Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Emmi YlikoskiDivision of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Risto O RoineDivision of Clinical Neurosciences, Neurology, Turku University Hospital, University of Turku, Turku, Finland.
Marjaana TiainenDepartment of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Harry ScheininDepartment of Perioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital and University of Turku, Turku, Finland.
Mervyn MazeDepartment of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, USA.
Tero VahlbergDepartment of Biostatistics, University of Turku, Turku University Hospital, Turku, Finland.
Timo T LaitioDepartment of Perioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital and University of Turku, Turku, Finland. timo.laitio@varha.fi.
Xe-HYPOTHECA Consortium

Funding

Swedish Research Council 2023-00356Swedish State Support for Clinical Research ALFGBG-71320The European Union's Horizon Europe research and innovation programme 101053962
6 · The paper itself

Abstract

Elevated levels of blood-based biomarkers such as neurofilament light chain (NfL) and neuron-specific enolase (NSE) are associated with poor neurological outcome after out-of-hospital cardiac arrest (OHCA). This study investigates the relationship between regional grey matter volume reduction and levels of glial fibrillary acidic protein (GFAP), NfL, NSE, and total-tau (t-tau) protein. This substudy of the Xe-Hypotheca trial included 110 patients randomized to receive either inhaled xenon with target temperature management (TTM) at 33 °C for 24 h (n = 55) or TTM alone (n = 55). Voxel-based morphometry was used to assess grey matter volume changes in MRI scans acquired 36-52 h and 10 days after OHCA in 45 survivors. Blood biomarkers were measured upon intensive care unit arrival and at 24, 48 and 72 h post-OHCA. NfL levels positively correlated with grey matter volume reduction in the thalamus and cingulate cortex at 24 h post-OHCA. T-tau showed more extensive pattern of significant correlations, increasing in both magnitude and spatial extent from baseline to 48 h post-OHCA. No significant biomarker-volume associations were observed for GFAP or NSE, and no treatment group differences were detected. Elevated NfL and t-tau levels were associated with region-specific grey matter volume reduction within the first 10 days after OHCA. Among the four biomarkers studied, t-tau demonstrated the strongest and most widespread associations, suggesting its potential as a marker for early ischemic grey matter volume reduction after OHCA. ClinicalTrials.gov NCT00879892, 13/04/2009.

Indexed as

BiomarkersGray MatterOut-of-Hospital Cardiac ArrestAgedBrainFemaleGlial Fibrillary Acidic ProteinHumansHypothermia, InducedMagnetic Resonance ImagingMaleMiddle AgedNeurofilament ProteinsPhosphopyruvate HydrataseSurvivorstau ProteinsBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsPhosphopyruvate Hydratasetau ProteinsBiomarkersMorphometryNeurofilament lightOut-of-hospital cardiac arrestTau proteinXenon

Identifiers

PMID41298726
PMCPMC12658190

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.